{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:50:46Z","timestamp":1777881046823,"version":"3.51.4"},"reference-count":69,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06646"],"award-info":[{"award-number":["21K06646"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K11100"],"award-info":[{"award-number":["21K11100"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medicine"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Ruxolitinib is used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease following allogeneic stem cell transplantation. This study aimed to determine the association between ruxolitinib and adverse events by evaluating case reports published between January 2014 and March 2024 in the Japanese Adverse Drug Event Report database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The signals for the ruxolitinib\u2013adverse event association were identified using propensity score-adjusted reporting odds ratio analysis. Data obtained from the drug\u2013gene interaction, drug signature, search tool for chemical interactions, and interaction reference index databases were used to construct a drug\u2013gene interaction network. Functional and pathway enrichment analyses were performed using the Disease Ontology Semantic and Enrichment and ReactomePA R packages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The propensity score-adjusted reporting odds ratio for ruxolitinib-associated adverse events was as follows: anemia, 18.49 (95% confidence interval (CI): 16.15\u201321.16); myelosuppression, 4.70 (95% CI: 3.54\u20136.24); pancytopenia, 1.97 (95% CI: 1.23\u20133.16); cardiac failure, 2.29 (95% CI: 1.60\u20133.28); hepatic function abnormal, 1.60 (95% CI: 1.15\u20132.23); herpes zoster, 6.40 (95% CI: 4.35\u20139.41); pneumonia, 2.96 (95% CI: 2.35\u20133.73); renal impairment, 1.34 (95% CI: 0.94\u20131.90); sepsis, 5.14 (95% CI: 3.75\u20137.05); interstitial lung disease, 0.33 (95% CI: 0.21\u20130.52); deep vein thrombosis, 0.32 (95% CI: 0.07\u20131.44); hemorrhage, 1.99 (95% CI: 1.05\u20133.75). We also assessed 3015 human genes that directly or indirectly interact with ruxolitinib. The molecular complex detection plug-in of Cytoscape was used to detect 24 clusters. Several genes were enriched in the biological processes of \u201canemia\u201d and \u201cbacterial infections,\u201d identified as significant ruxolitinib-related disease terms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This retrospective analysis using the Japanese Adverse Drug Event Report database indicated potential associations between ruxolitinib and adverse events, including anemia and bacterial infections. Future research should explore the underlying pharmacological mechanisms using functional enrichment analysis of ruxolitinib-associated genes related to blood toxicity and bacterial infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20503121251348420","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T06:48:37Z","timestamp":1750747717000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of adverse events with ruxolitinib using real-world datasets and drug-interaction networks"],"prefix":"10.1177","volume":"13","author":[{"given":"Hideyuki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"},{"name":"Chubuyakuhin Co., Ltd., Tajimi-shi, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-1351","authenticated-orcid":false,"given":"Mika","family":"Maezawa","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryogo","family":"Umetsu","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakiko","family":"Hirofuji","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koumi","family":"Miyasaka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7413-2637","authenticated-orcid":false,"given":"Satoshi","family":"Nakao","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"},{"name":"Department of Pharmacy, Kyushu University Hospital, Higashi-ku, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Nokura","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanaka","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Sugishita","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shiota","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4543-1176","authenticated-orcid":false,"given":"Hirofumi","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Laboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-5522","authenticated-orcid":false,"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30207-8"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954268"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.03.041"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3519"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206690"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12617"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18504"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.764279"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07429"},{"key":"e_1_3_3_19_2","unstructured":"The pharmaceuticals and medical devices agency Entity Relation (ER) diagram for each table in JADER https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0004.html (2025 accessed 4 May 2025)."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.5772\/50095"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190102"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.43789"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-405"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-4-2"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1239303"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu684"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00663E"},{"issue":"7","key":"e_1_3_3_33_2","first-page":"706","article-title":"Clarifying the use of ruxolitinib in patients with myelofibrosis","volume":"27","author":"Kremyanskaya M","year":"2013","unstructured":"Kremyanskaya M, Atallah EL, Hoffman R, et al. Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology (Williston Park) 2013; 27(7): 706\u2013714.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_3_34_2","unstructured":"An Official Website of U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death (2022 accessed 9 November 2024)."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01082-y"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.32598\/PBR.10.3.1207.3"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(96)00121-0"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl2097"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137109"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092585"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2994-x"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635235"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.07.010"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101270"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.7.2264"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.812431"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl0368"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24452"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01393"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01826-7"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01468-7"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224049"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730100-00007"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01569.x"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831070-00006"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124030-00006"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.8.743.36068"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1633"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-021-00513-x"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8457"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00957.x"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b14-00191"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b17-00266"},{"key":"e_1_3_3_67_2","unstructured":"Novarits. JAKAVI\u00ae tablet oral solution. Package insert https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/300242_4291034F1029_1_13 (2025 accessed 4 May 2025)."},{"key":"e_1_3_3_68_2","unstructured":"Schuemie MJ Ryan PB Hripcsak G et al. A systematic approach to improving the reliability and scale of evidence from health care data. arVix https:\/\/arxiv.org\/pdf\/1803.10791.pdf (2018 accessed 4 May 2025)."},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyy120"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1510502113"}],"container-title":["Sage Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251348420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20503121251348420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251348420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:40Z","timestamp":1777595440000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20503121251348420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":69,"alternative-id":["10.1177\/20503121251348420"],"URL":"https:\/\/doi.org\/10.1177\/20503121251348420","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"20503121251348420"}}